Longeveron Inc. — Form 8-K
Filed August 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Longeveron appointed Nirav Jhaveri as CFO effective August 17, 2026, replacing Marie Washburn. Jhaveri receives a $400,000 base salary, 45% target bonus, and 300,000 RSUs vesting quarterly over 3 years. He brings 25+ years of capital markets and biotech experience, including prior CFO roles at public companies (Opus Genetics, Journey Medical) and tenure at Fortress Biotech, Citigroup, and Bank of America.
Why this rating
Routine executive appointment with standard compensation. Jhaveri's biotech experience is relevant; however, this is a CFO hire at a $16.5M market-cap clinical stage biotech, not a transformational event. Timing near Phase 2b trial readout (September 2026) suggests better capital management, but appointment alone is administrative.
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.